In a randomized, double‐blind Phase 2 study involving 120 adults with obesity but without diabetes, Amgen’s weekly dosing cohort achieved a mean weight reduction of 12.3% over 24 weeks, while the cohort receiving the investigational agent every two weeks saw a 10.1% reduction. Both regimens outperformed placebo by more than 6 percentage points (p<0.001). The every‐two‐weeks dosing arm also reported comparable improvements in systolic blood pressure (–8.5 mmHg) and LDL cholesterol (–15.2 mg/dL), suggesting that less frequent administration does not compromise metabolic benefits.

Adverse events in the bi-weekly dosing group were predominantly mild to moderate gastrointestinal symptoms, with nausea reported in 18% of participants versus 22% in the weekly arm. Injection‐site reactions occurred in 5% of subjects on the extended schedule, down from 9% in the weekly cohort. No serious adverse events related to the study drug were observed, and treatment discontinuation rates were low (3.3% bi-weekly; 4.2% weekly), reinforcing the potential for improved patient adherence and reduced administration burden.

By positioning its candidate with a less frequent dosing schedule, Amgen aims to differentiate from established peers in the weight-loss market. The company plans to initiate a 600-patient Phase 3 program in Q2 2026, targeting regulatory submissions in both the U.S. and Europe by mid-2028. Analysts estimate that if approved, the therapy could capture 15–20% of the global anti-obesity market by 2030, translating into peak annual sales of approximately $3 billion. Investors will monitor enrollment progress and interim safety readouts as key catalysts ahead of full Phase 3 data.